证券代码：600568 证券简称：ST 中珠 公告编号：2022-070 号 中珠医疗控股股份有限公司 2023 年半年度募集资金存放与使用情况的专项报告 特别提示 本公司董事及董事会全体成员保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据《上海证券交易所上市公司募集资金管理办法（2013 修订）》和《上市公司 监管指引第 2 号——上市公司募集资金管理和使用的监管要求（2022 年修订）》的规 定，中珠医疗控股股份有限公司（以下简称"公司"、"本公司"）将 2023 年半年度 募集资金存放与实际使用情况专项说明如下： 一、 募集资金基本情况 重大资产重组募集配套资金基本情况 根据本公司 2015 年 9 月第七届董事会第四十一次会议和 2015 年 10 月第一次临时 股东大会会议，并经中国证券监督管理委员会《关于核准中珠控股股份有限公司向深 圳市一体投资控股集团有限公司等发行股份购买资产并募集配套资金的批复》（证监许 可[2016]226 号）文件核准，本公司向深圳市一体投资控股集团有限公司发行 96,071,607 股股份、向深圳市 ...

我局在日常监管中关注到你公司存在以下违规事实: 索 引 号 bm56000001/2023-00009072 分 类 发布机构 发文日期 1691427403000 湖北证监局关于对深圳市朗地科技发展有限公司采取出具警示函措施 的决定 深圳市朗地科技发展有限公司: 湖北证监局 2023年8月8日 【打印】 【关闭窗口】 名 称 湖北证监局关于对深圳市朗地科技发展有限公司采取出具警示函措施的决定 文 号 〔2023〕24号 主 题 词 2020年10月,你公司通过司法拍卖竞得中珠医疗控股股份有限公司(以下简称ST中珠)6.415%的股份, 并于2020年12月完成股权过户登记手续,首次成为ST中珠持股5%以上股东。12月4日,你公司披露《简式 权益变动报告书》,在报告书中未披露你公司股东黄新浩、黄超二人与深圳市深商控股集团股份有限公 司(以下简称深商控股)签署了《代持协议》,黄新浩、黄超持有的你公司100%的股权实际为代深商控股 持有。2022年8月,你公司再次通过司法拍卖竞得ST中珠12.66%的股份。2023年1月,你公司披露前述股权 代持关系。 你公司在首次成为ST中珠5%以上股东时,未准确披露股东情况, ...

证券代码：600568 证券简称：ST 中珠 公告编号：2023-067 号 中珠医疗控股股份有限公司 关于公司持股 5%以上股东部分股份解除质押及再质押的公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: 截止本公告日，中珠医疗控股股份有限公司（以下简称"中珠医疗"或"公 司"）股东广州云鹰资本管理有限公司（以下简称"云鹰资本"）持有公司无限售流 通股 142,266,541 股，占公司总股本的 7.14%。本次解除质押股份数量 102,409,034 股，再质押股份数量 50,000,000 股，本次股份解除质押及再质押后，云鹰资本累计 质押数量为50,000,000股，占其持有公司股份总数的35.15%，占公司总股本的2.51%。 中珠医疗于 2023 年 8 月 17 日收到公司持股 5%以上股东云鹰资本关于股份解除 质押及再质押的通知，具体情况如下： 一、上市公司股份解除质押及再质押基本情况 1、本次股份解除质押情况 本次股份解除质押后用于后续再质押，详见"2、本次股份再质押基本情况 ...

证券代码：600568 证券简称：ST 中珠 公告编号：2023-066 号 中珠医疗控股股份有限公司 关于控股子公司利用闲置资金委托理财的进展公告 委托理财受托方：交通银行股份有限公司 本次委托理财金额：人民币 1,500 万元 委托理财产品名称：交通银行蕴通财富定期型结构性存款 35 天（挂钩汇率看涨） 委托理财期限：35 天 履行的审议程序：中珠医疗控股股份有限公司（以下简称"中珠医疗"或"公 司"）于 2023 年 5 月 23 日召开第九届董事会第三十九次会议，审议通过了《关 于控股子公司利用闲置资金委托理财的议案》，同意公司控股子公司广西玉林市 桂南医院有限公司（以下简称"桂南医院"）使用最高额度不超过人民币 8,000 万元的闲置资金购买国有银行或股份制银行自主发行的中低风险理财产品及券 商发行的收益凭证。本次理财额度期限自董事会批准之日起一年内有效，在上 述期限内，资金额度可以滚动使用。公司独立董事对以上事项发表了同意的独 立意见。 （一）委托理财目的：公司控股子公司根据财务和资金状况，在不影响公司正常经 营及风险可控的前提下，使用部分闲置自有资金进行短期理财，最大限度地提高资金运 营效益，为 ...

重要内容提示： 证券代码：600568 证券简称：ST 中珠 公告编号：2023-065 号 中珠医疗控股股份有限公司 关于控股子公司利用闲置资金委托理财的进展公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 （二）资金来源：公司控股子公司桂南医院闲置自有资金。 （三）委托理财产品的基本情况 | 受托方 | 产品类 | 产品名称 | 金额 | 投资者年化 | 预计收益金 | 产品期限 | 收益 | 是否 构成 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 型 | | （万元） | 收益率 | 额（万元） | | 类型 | 关联 | | | | | | | | | | 交易 | | 交通银 行股份 | | 交通银行蕴通财 | | | | | 保本 | | | | 结构性 | 富定期型结构性 | 500 | 1.25%-2.30% | 0.61-1.12 | 35 天 | 浮动 | 否 | | 有限公 | 存款 | 存款 35 ...

证券代码：600568 证券简称：ST 中珠 公告编号：2023-064 号 中珠医疗控股股份有限公司 根据《上市公司收购管理办法》第七十五条的规定，我局决定对你公司采取出 具警示函的行政监管措施，并记入证券期货市场诚信档案。你公司应当吸取教训， 关于收到湖北证监局对公司股东深圳市朗地科技发展有限公 司采取出具警示函措施决定的公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 中珠医疗控股股份有限公司于2023年8月8日收到中国证券监督管理委员会湖北 监管局《湖北证监局关于对深圳市朗地科技发展有限公司采取出具警示函措施的决 定》的行政监管措施决定书（[2023]24号）（以下简称"《决定书》"）,现将《决 定书》全文公告如下： "深圳市朗地科技发展有限公司： 我局在日常监管中关注到你公司存在以下违规事实： 2020年10月，你公司通过司法拍卖竞得中珠医疗控股股份有限公司(以下简称ST 中珠)6.415%的股份，并于2020年12月完成股权过户登记手续，首次成为ST中珠持股 5%以上股东。12月4日，你公司披露 ...

证券代码：600568 证券简称：ST 中珠 公告编号：2023-044 号 中珠医疗控股股份有限公司 关于召开 2022 年度业绩说明会的公告 特别提示 本公司及董事会全体成员保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 05 月 09 日（星期二）至 05 月 15 日（星期一）16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 zz600568@126.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 中珠医疗控股股份有限公司（以下简称"中珠医疗"或"公司"）已于 2023 年 4 月 20 日发布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年度 经营成果、财务状况，公司计划于 2023 年 5 月 16 日（星期二）上午 10:00-11:00 举 行 2022 年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度的经营成果及财 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 117,820,377.20, representing a decrease of 3.82% compared to the same period last year[5]. - The net profit attributable to shareholders was a loss of CNY 27,828,721.13, a significant decline of 577.44% year-on-year[5]. - Basic and diluted earnings per share were both CNY -0.0140, reflecting a decrease of 566.67% compared to the same period last year[6]. - Total operating revenue for Q1 2023 was ¥117,820,377.20, a decrease of 3.5% compared to ¥122,493,820.06 in Q1 2022[20]. - Net profit for Q1 2023 was a loss of ¥21,844,934.44, compared to a profit of ¥1,621,721.13 in Q1 2022[21]. - The total comprehensive loss for Q1 2023 was ¥21,955,975.58, compared to a comprehensive income of ¥1,622,794.27 in Q1 2022[22]. Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY 55,884,126.32, down 71.31% from the previous year[5]. - Cash flow from operating activities increased significantly to ¥153,428,109.94 in Q1 2023, compared to ¥97,155,935.90 in Q1 2022, representing a growth of 57.9%[24]. - The net cash flow from operating activities was -$55.88 million, compared to -$32.62 million in the previous year, indicating a decline in operational performance[25]. - Cash and cash equivalents were reported at RMB 515,850,737.83, a decrease from RMB 577,180,844.05, reflecting a decline of approximately 10.65%[17]. - Cash and cash equivalents at the end of the period totaled $331.13 million, down from $562.68 million at the end of the previous year[26]. - The net increase in cash and cash equivalents was -$62.80 million, contrasting with a positive increase of $35.34 million in the previous year[26]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,640,085,392.25, a decrease of 1.96% from the end of the previous year[6]. - The company's current assets totaled RMB 1,771,922,816.09, down from RMB 1,839,334,761.76, indicating a decrease of about 3.67%[18]. - The company's total liabilities decreased to ¥725,342,877.67 in Q1 2023 from ¥775,972,082.61 in Q1 2022, a reduction of approximately 6.5%[20]. - The company's long-term equity investments stood at RMB 349,482,036.42, a minor decrease from RMB 352,514,093.13, representing a decline of approximately 0.91%[18]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 24,739[13]. - The top shareholder, Shenzhen Landi Technology Development Co., Ltd., holds 19.08% of the shares, with 380,172,862 shares pledged[13]. Expenses and Costs - The company experienced a 31.38% increase in sales expenses, attributed to higher costs in the pharmaceutical sector[11]. - Total operating costs increased to ¥136,899,729.17 in Q1 2023, up 7.4% from ¥126,995,078.54 in Q1 2022[20]. - Research and development expenses rose to ¥4,555,699.77 in Q1 2023, up from ¥3,727,371.97 in Q1 2022, indicating an increase of 22.2%[21]. - Cash paid for purchasing goods and services was $51.50 million, down from $65.75 million in the previous year, indicating cost control measures[25]. - The company paid $61.32 million in employee compensation, an increase from $51.68 million in the previous year, reflecting higher labor costs[25]. Investment and Future Outlook - The company reported an investment loss of ¥1,065,207.38 in Q1 2023, compared to a gain of ¥1,473,744.90 in Q1 2022[21]. - The company has not disclosed any new product developments or technological advancements in the provided documents[16]. - There were no significant updates regarding market expansion or mergers and acquisitions mentioned in the conference call[16]. - The company has not provided specific future guidance or performance outlook in the available reports[16].

Financial Performance - The company reported a net profit attributable to the parent company of -¥799,221,521.72 for the year 2022, with a parent company net profit of -¥296,662,674.12[6] - The undistributed profits at the beginning of the year were -¥1,501,827,304.05, and by the end of 2022, they decreased to -¥2,301,048,825.77[6] - The company will not distribute cash dividends, issue bonus shares, or increase capital from reserves for the year 2022 due to the negative profit situation[6] - The company's operating revenue for 2022 was approximately ¥505.97 million, a decrease of 12.92% compared to ¥581.06 million in 2021[27] - The net profit attributable to shareholders for 2022 was approximately -¥799.22 million, representing a significant decline of 278.27% from -¥211.28 million in 2021[27] - The net cash flow from operating activities decreased by 72.86% to approximately ¥25.52 million in 2022, down from ¥94.04 million in 2021[27] - The total assets at the end of 2022 were approximately ¥3.71 billion, a decrease of 16.72% from ¥4.46 billion at the end of 2021[27] - The net assets attributable to shareholders decreased by 22.23% to approximately ¥2.80 billion at the end of 2022, down from ¥3.60 billion at the end of 2021[27] - The basic earnings per share for 2022 was -¥0.4010, a decline of 278.30% compared to -¥0.1060 in 2021[28] - The weighted average return on net assets for 2022 was -24.99%, a decrease of 19.26 percentage points from -5.73% in 2021[29] Debt and Financial Risks - As of the end of 2022, funds occupied by related parties amounted to ¥567,988,400, which is 20.30% of the company's audited net assets[9] - The company has faced a significant risk due to the failure to clear or rectify the fund occupation within one month, leading to continued risk warning for its stock[9] - The company holds a total debt of ¥313,335,013.80 against a related party currently undergoing bankruptcy liquidation[11] - The company reported a total debt of 313,335,013.80 CNY owed to Yiti Group, classified as unsecured debt[164] - As of the end of 2022, the funds occupied by Zhongzhu Group and other related parties amounted to 56,798.84 CNY, representing 20.30% of the company's audited net assets[166] Shareholder Changes and Governance - The largest shareholder, Langdi Technology, acquired 19.077% of the company's shares, becoming the first major shareholder[13] - A significant change in the company's major shareholders has occurred, leading to potential uncertainties regarding control changes[14] - The company has faced risks related to the potential change in control due to significant shareholder changes[165] - The company has experienced significant changes in its major shareholders, with Langdi Technology becoming the largest shareholder holding 19.077% of the total shares[165] - The company has established a complete independent business system, maintaining operational independence from its controlling shareholder[170] Audit and Compliance - The company received a qualified audit opinion from Dahua Certified Public Accountants for its 2022 financial statements[5] - The company emphasizes transparency in information disclosure, adhering to legal requirements and ensuring all shareholders have equal access to information[174] - The company has committed to rectifying past compliance issues, as indicated by the conclusion of investigations without administrative penalties in 2021[192] - The company faced public reprimands from the Shanghai Stock Exchange for information disclosure violations involving its major shareholders and executives[193] - The company is required to strengthen internal management to prevent future violations of information disclosure regulations[194] Strategic Focus and Future Plans - The company plans to focus on new product development and market expansion strategies in the upcoming fiscal year[27] - The company plans to strengthen its operations in the pharmaceutical, medical, and real estate sectors, focusing on resource integration and strategic adjustments[36] - The company aims to maintain steady growth in its pharmaceutical, medical, and real estate sectors while fulfilling its social responsibilities[73] - The company is exploring market expansion opportunities and potential mergers and acquisitions as part of its growth strategy in response to industry consolidation trends[143] - The company will prioritize asset revitalization and industry structure transformation, enhancing product competitiveness and expanding sales channels across its pharmaceutical and hospital sectors[148] Research and Development - The company continues to focus on innovation in drug development and has received multiple awards for its research projects[72] - The company is advancing the research and development of the SCM-198 project, which is aimed at lowering blood lipids and preventing strokes, with ongoing clinical trials[77] - The company’s subsidiary has completed the Phase II clinical research for Genistein capsules and is progressing to Phase III studies[78] - The company has exclusive rights to 8 patents related to SCM-198, which is aimed at cardiovascular disease prevention and treatment[123] - The company is actively pursuing FDA submissions for SCM-198 as part of its development strategy[123] Market Conditions and Industry Trends - The real estate market in China is experiencing a downturn, with a focus on stabilizing policies to support housing demand and prevent systemic risks in the industry[57] - The government emphasizes that housing is for living, not speculation, and is implementing measures to support rigid and improved housing needs[58] - The healthcare industry is expected to grow significantly, with the government aiming to enhance the medical service system by 2025, improving resource allocation and emergency response capabilities[55] - The pharmaceutical industry in China is expanding rapidly, with a focus on high-quality development and compliance with new regulations[54] - The medical device industry in China is becoming a major emerging market, with domestic innovation accelerating the development and market entry of new products[112] Management and Governance - The company appointed Wang Bo as the new CEO on November 22, 2022, with a term until the completion of the current board's term[181] - The company appointed Huang Guanghui as the Executive Vice President on December 23, 2022, with a term until the completion of the current board's term[182] - The company’s Vice President, Si Peichao, was promoted from Executive Vice President on December 23, 2022[182] - The management team includes individuals with extensive experience in various sectors, enhancing the company's operational capabilities[181] - The company has established a remuneration and assessment committee to determine the compensation of directors and senior management, ensuring alignment with the company's assessment system[187]

Financial Position and Performance - The company reported a net asset of 56,798.84 million yuan occupied by related parties, which is 15.79% of the audited net assets as of the end of 2021[8]. - The company has a total debt claim against Yiti Group amounting to 313,335,013.80 yuan, with no property collateral[10]. - The company’s stock continues to be under risk warning due to the financial issues with related parties[8]. - The company’s operating revenue for the first half of 2022 was RMB 252.50 million, representing a 10.21% increase compared to RMB 229.10 million in the same period last year[24]. - The net profit attributable to shareholders of the listed company improved to a loss of RMB 27.20 million, a 43.43% reduction from a loss of RMB 48.08 million in the previous year[24]. - The net cash flow from operating activities was RMB 10.32 million, a significant turnaround from a negative cash flow of RMB 99.53 million in the same period last year, marking an increase of 110.37%[24]. - The total assets at the end of the reporting period were RMB 4.41 billion, down 1.08% from RMB 4.46 billion at the end of the previous year[24]. - The net assets attributable to shareholders of the listed company decreased slightly by 0.76% to RMB 3.57 billion from RMB 3.60 billion at the end of the previous year[24]. - The basic earnings per share improved to -0.0136 yuan per share, a 43.57% increase compared to -0.0241 yuan per share in the same period last year[25]. - The weighted average return on net assets increased by 0.52 percentage points to -0.7588% from -1.2746% in the previous year[25]. - The company received government subsidies amounting to RMB 13.67 million, which are closely related to its normal business operations[26]. Shareholding and Control - As of the announcement date, Yiti Group holds 12.661% of the company's total shares, which is 252,324,862 shares[11]. - On August 5, 2022, Landi Technology won the auction for Yiti Group's shares in the company for 439,423,747.17 yuan, which represents 12.661% of the total shares[12]. - The total shares held by Yiti Group and its concerted actors amount to 324,156,729 shares, representing 16.266% of the total share capital[78]. - The first extraordinary shareholders' meeting in 2022 had a total of 123,056,061 shares represented, accounting for 41.2126% of the voting shares[83]. - The company has a significant concentration of shareholding, with multiple shareholders holding over 5% of the total shares, indicating potential uncertainty in control changes[80]. - The company has committed to not transferring shares held prior to the issuance for 12 months and shares subscribed in the private placement for 36 months[91]. - The company has ensured that any necessary related party transactions will be conducted at market prices to minimize and avoid related party transactions[92]. Legal and Regulatory Matters - The company has taken legal action to recover compensation from Yiti Group for unfulfilled performance commitments, amounting to 17,423,025 shares[10]. - The company has reported a series of legal disputes affecting its financial position, with ongoing litigation impacting its operational strategy[103]. - The company is actively pursuing recovery of debts through legal channels to safeguard its financial interests[102]. - The company is involved in a civil lawsuit regarding the acquisition of Aide Hospital, with a claim amount of RMB 50 million[104]. - The company has a pending civil lawsuit with Zheshang Bank, claiming RMB 25 million due to management failures related to a contractual commitment[104]. - The company has won a first-instance judgment in a lawsuit against Shen Mimi, with the claim amount being RMB 25,732.25[104]. - The company has reported no significant litigation or arbitration matters during the reporting period[101]. Business Segments and Operations - The pharmaceutical segment focuses on the research, production, and sales of specialized ophthalmic drugs, with key products including eye drops and tablets, and ongoing projects like SCM-198 for lipid-lowering and stroke prevention[30]. - In the medical sector, the company operates tumor treatment products, with 13 collaborative tumor radiotherapy centers, of which 5 are currently operational[31]. - The real estate segment is primarily engaged in residential property development in Zhuhai, with 4 projects currently for sale, including the Shanhai Jian Phase II project[32]. - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[24]. - The company has a strategic goal of developing a full industry chain in anti-tumor services, enhancing its operational management capabilities[33]. - The company is committed to innovation in drug development, combining in-house research with external partnerships[30]. Financial Management and Strategy - The company emphasized cost management, implementing budget management to control expenditures effectively[47]. - Continuous investment in new drug research and development and core technology for medical devices was maintained to enhance market competitiveness[48]. - The company plans to continue improving its financial performance and operational efficiency in the upcoming quarters[24]. - The company completed the liquidation of two entities to reduce investment risks and improve operational efficiency[46]. - The company focused on optimizing its asset structure and established two new subsidiaries in real estate and property management[46]. Market and Economic Environment - The healthcare industry is characterized by strong demand resilience, with ongoing reforms expected to expand the overall market capacity[38]. - The real estate sector is experiencing a shift from deleveraging to stabilizing leverage, with government support aimed at restoring market confidence and normalizing transactions[37]. - The pharmaceutical industry faced significant operational impacts due to the pandemic, but production gradually resumed as the situation improved[36]. - The Ministry of Industry and Information Technology and other departments issued the "14th Five-Year Plan for Pharmaceutical Industry Development," emphasizing innovation in product development and improving industrial technology levels[36]. Corporate Governance and Compliance - The financial statements were approved by the board of directors on August 30, 2022, ensuring compliance with regulatory requirements[169]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring that its financial reports accurately reflect its financial position and performance[175]. - The company has not reported any changes in the accounting policies or prior period error corrections during the current period[158]. - The company has not disclosed any significant related party transactions during the reporting period[109]. - The company has not engaged in any major asset acquisitions or sales during the reporting period[110].